

RAW SEQUENCE LISTING

**The Biotechnology Systems Branch of the Scientific and Technical
Information Center (STIC) no errors detected.**

Application Serial Number: 10|550,632
Source: JFWO
Date Processed by STIC: 12/7/06

ENTERED



IFWO

RAW SEQUENCE LISTING

DATE: 12/07/2006

PATENT APPLICATION: US/10/550,632

TIME: 14:17:58

Input Set : N:\efs\12_07_06\10550632_efs\seqlist.txt

Output Set: N:\CRF4\12072006\J550632.raw

```

4 <110> APPLICANT: Argoud-Puy, Guilaine
5      Bederr, Nassima
6      Bougueleret, Lydie
7      Cusin, Isabelle
8      Mah?, Eve
9      Niknejad, Anne
10     Reffas, Samia
13 <120> TITLE OF INVENTION: SECRETED POLYPEPTIDE SPECIES ASSOCIATED
14     WITH CARDIOVASCULAR DISORDERS
17 <130> FILE REFERENCE: 33624 US-PCT GEP5032
19 <140> CURRENT APPLICATION NUMBER: 10/550,632
C--> 20 <141> CURRENT FILING DATE: 2005-09-23
22 <150> PRIOR APPLICATION NUMBER: 60/461,558
23 <151> PRIOR FILING DATE: 2003-04-08
25 <150> PRIOR APPLICATION NUMBER: 60/461,623
26 <151> PRIOR FILING DATE: 2003-04-08
28 <150> PRIOR APPLICATION NUMBER: 60/471,479
29 <151> PRIOR FILING DATE: 2003-05-16
31 <150> PRIOR APPLICATION NUMBER: 60/474,863
32 <151> PRIOR FILING DATE: 2003-05-30
34 <150> PRIOR APPLICATION NUMBER: 60/484140
35 <151> PRIOR FILING DATE: 2003-06-30
37 <150> PRIOR APPLICATION NUMBER: PCT/EP2004/003737
38 <151> PRIOR FILING DATE: 2004-04-07
40 <160> NUMBER OF SEQ ID NOS: 147
42 <170> SOFTWARE: FastSEQ for Windows Version 4.0
44 <210> SEQ ID NO: 1
45 <211> LENGTH: 95
46 <212> TYPE: PRT
47 <213> ORGANISM: Homo sapiens
49 <220> FEATURE:
50 <221> NAME/KEY: PEPTIDE
51 <222> LOCATION: (1)...(95)
52 <223> OTHER INFORMATION: A Cardiovascular disorder Plasma Polypeptide 2
53     (CPP-2) peptide. SEQ ID NOS:1 and 2 describe the
54     amino acid sequences of the Colipase polypeptides
55     present in plasma samples of individuals with
W--> 56     coronary artery disease (hereinafter SEQ ID NO:2
W--> 57     is designated CPP-2).
59 <400> SEQUENCE: 1
60 Ala Pro Gly Pro Arg Gly Ile Ile Ile Asn Leu Glu Asn Gly Glu Leu
61 1          5          10          15
62 Cys Met Asn Ser Ala Gln Cys Lys Ser Asn Cys Cys Gln His Ser Ser

```

RAW SEQUENCE LISTING

DATE: 12/07/2006

PATENT APPLICATION: US/10/550,632

TIME: 14:17:58

Input Set : N:\efs\12_07_06\10550632_efs\seqlist.txt

Output Set: N:\CRF4\12072006\J550632.raw

```

63          20          25          30
64 Ala Leu Gly Leu Ala Arg Cys Thr Ser Met Ala Ser Glu Asn Ser Glu
65          35          40          45
66 Cys Ser Val Lys Thr Leu Tyr Gly Ile Tyr Tyr Lys Cys Pro Cys Glu
67          50          55          60
68 Arg Gly Leu Thr Cys Glu Gly Asp Lys Thr Ile Val Gly Ser Ile Thr
69 65          70          75          80
70 Asn Thr Asn Phe Gly Ile Cys His Asp Ala Gly Arg Ser Lys Gln
71          85          90          95
74 <210> SEQ ID NO: 2
75 <211> LENGTH: 90
76 <212> TYPE: PRT
77 <213> ORGANISM: Homo sapiens
79 <220> FEATURE:
80 <221> NAME/KEY: PEPTIDE
81 <222> LOCATION: (1)...(90)
82 <223> OTHER INFORMATION: A Cardiovascular disorder Plasma Polypeptide 2
83 (CPP-2) peptide. SEQ ID NOs:1 and 2 describe the
84 amino acid sequences of the Colipase polypeptides
85 present in plasma samples of individuals with
W--> 86 coronary artery disease (hereinafter, SEQ ID NO:2
W--> 87 is designated CPP 2).
89 <400> SEQUENCE: 2
90 Gly Ile Ile Ile Asn Leu Glu Asn Gly Glu Leu Cys Met Asn Ser Ala
91 1          5          10          15
92 Gln Cys Lys Ser Asn Cys Cys Gln His Ser Ser Ala Leu Gly Leu Ala
93          20          25          30
94 Arg Cys Thr Ser Met Ala Ser Glu Asn Ser Glu Cys Ser Val Lys Thr
95          35          40          45
96 Leu Tyr Gly Ile Tyr Tyr Lys Cys Pro Cys Glu Arg Gly Leu Thr Cys
97          50          55          60
98 Glu Gly Asp Lys Thr Ile Val Gly Ser Ile Thr Asn Thr Asn Phe Gly
99 65          70          75          80
100 Ile Cys His Asp Ala Gly Arg Ser Lys Gln
101          85          90
104 <210> SEQ ID NO: 3
105 <211> LENGTH: 14
106 <212> TYPE: PRT
107 <213> ORGANISM: Homo sapiens
109 <220> FEATURE:
110 <221> NAME/KEY: PEPTIDE
111 <222> LOCATION: (1)...(14)
112 <223> OTHER INFORMATION: A Cardiovascular disorder Plasma Polypeptide 2
113 (CPP-2) peptide. EQ ID NOs:3-5 are the amino acid
114 sequences of tryptic peptides found in MS-MS
115 and/or MS-MALDI mass spectrometry in plasma
W--> 116 samples of individuals with coronary artery
W--> 117 disease.
119 <400> SEQUENCE: 3

```

RAW SEQUENCE LISTING

DATE: 12/07/2006

PATENT APPLICATION: US/10/550,632

TIME: 14:17:58

Input Set : N:\efs\12_07_06\10550632_efs\seqlist.txt

Output Set: N:\CRF4\12072006\J550632.raw

```

120 Ser Asn Cys Cys Gln His Ser Ser Ala Leu Gly Leu Ala Arg
121 1 5 10
124 <210> SEQ ID NO: 4
125 <211> LENGTH: 14
126 <212> TYPE: PRT
127 <213> ORGANISM: Homo sapiens
129 <220> FEATURE:
130 <221> NAME/KEY: PEPTIDE
131 <222> LOCATION: (1)...(14)
132 <223> OTHER INFORMATION: A Cardiovascular disorder Plasma Polypeptide 2
133 (CPP-2) peptide. EQ ID NOs:3-5 are the amino acid
134 sequences of tryptic peptides found in MS-MS
135 and/or MS-MALDI mass spectrometry in plasma
W--> 136 samples of individuals with coronary artery
W--> 137 disease.
139 <400> SEQUENCE: 4
140 Cys Thr Ser Met Ala Ser Glu Asn Ser Glu Cys Ser Val Lys
141 1 5 10
144 <210> SEQ ID NO: 5
145 <211> LENGTH: 19
146 <212> TYPE: PRT
147 <213> ORGANISM: Homo sapiens
149 <220> FEATURE:
150 <221> NAME/KEY: PEPTIDE
151 <222> LOCATION: (1)...(19)
152 <223> OTHER INFORMATION: A Cardiovascular disorder Plasma Polypeptide 2
153 (CPP-2) peptide. EQ ID NOs:3-5 are the amino acid
154 sequences of tryptic peptides found in MS-MS
155 and/or MS-MALDI mass spectrometry in plasma
W--> 156 samples of individuals with coronary artery
W--> 157 disease.
159 <400> SEQUENCE: 5
160 Thr Ile Val Gly Ser Ile Thr Asn Thr Asn Phe Gly Ile Cys His Asp
161 1 5 10 15
162 Ala Gly Arg
166 <210> SEQ ID NO: 6
167 <211> LENGTH: 161
168 <212> TYPE: PRT
169 <213> ORGANISM: Homo sapiens
171 <220> FEATURE:
172 <221> NAME/KEY: PEPTIDE
173 <222> LOCATION: (1)...(161)
174 <223> OTHER INFORMATION: A Cardiovascular disorder Plasma Polypeptide 9
175 (CPP-9) peptide. SEQ ID NO:6 describes the amino
176 acid sequence of eosinophil-derived neurotoxin
177 (EDN, hereinafter CPP-9), whereas SEQ ID NO:7 is
W--> 178 the polypeptide sequence of the mature protein.
180 <400> SEQUENCE: 6
181 Met Val Pro Lys Leu Phe Thr Ser Gln Ile Cys Leu Leu Leu Leu

```

RAW SEQUENCE LISTING

DATE: 12/07/2006

PATENT APPLICATION: US/10/550,632

TIME: 14:17:58

Input Set : N:\efs\12_07_06\10550632_efs\seqlist.txt

Output Set: N:\CRF4\12072006\J550632.raw

```

182 1           5           10           15
183 Gly Leu Leu Ala Val Glu Gly Ser Leu His Val Lys Pro Pro Gln Phe
184           20           25           30
185 Thr Trp Ala Gln Trp Phe Glu Thr Gln His Ile Asn Met Thr Ser Gln
186           35           40           45
187 Gln Cys Thr Asn Ala Met Gln Val Ile Asn Asn Tyr Gln Arg Arg Cys
188           50           55           60
189 Lys Asn Gln Asn Thr Phe Leu Leu Thr Thr Phe Ala Asn Val Val Asn
190 65           70           75           80
191 Val Cys Gly Asn Pro Asn Met Thr Cys Pro Ser Asn Lys Thr Arg Lys
192           85           90           95
193 Asn Cys His His Ser Gly Ser Gln Val Pro Leu Ile His Cys Asn Leu
194           100          105          110
195 Thr Thr Pro Ser Pro Gln Asn Ile Ser Asn Cys Arg Tyr Ala Gln Thr
196           115          120          125
197 Pro Ala Asn Met Phe Tyr Ile Val Ala Cys Asp Asn Arg Asp Gln Arg
198           130          135          140
199 Arg Asp Pro Pro Gln Tyr Pro Val Val Pro Val His Leu Asp Arg Ile
200 145          150          155          160
201 Ile

```

205 <210> SEQ ID NO: 7

206 <211> LENGTH: 134

207 <212> TYPE: PRT

208 <213> ORGANISM: Homo sapiens

210 <220> FEATURE:

211 <221> NAME/KEY: PEPTIDE

212 <222> LOCATION: (1)...(134)

213 <223> OTHER INFORMATION: A Cardiovascular disorder Plasma Polypeptide 9

214 (CPP-9) peptide. SEQ ID NO:6 describes the amino

215 acid sequence of eosinophil-derived neurotoxin

216 (EDN, hereinafter CPP-9), whereas SEQ ID NO:7 is

W--> 217 the polypeptide sequence of the mature protein.

219 <400> SEQUENCE: 7

```

220 Lys Pro Pro Gln Phe Thr Trp Ala Gln Trp Phe Glu Thr Gln His Ile
221 1           5           10           15
222 Asn Met Thr Ser Gln Gln Cys Thr Asn Ala Met Gln Val Ile Asn Asn
223           20           25           30
224 Tyr Gln Arg Arg Cys Lys Asn Gln Asn Thr Phe Leu Leu Thr Thr Phe
225           35           40           45
226 Ala Asn Val Val Asn Val Cys Gly Asn Pro Asn Met Thr Cys Pro Ser
227           50           55           60
228 Asn Lys Thr Arg Lys Asn Cys His His Ser Gly Ser Gln Val Pro Leu
229 65           70           75           80
230 Ile His Cys Asn Leu Thr Thr Pro Ser Pro Gln Asn Ile Ser Asn Cys
231           85           90           95
232 Arg Tyr Ala Gln Thr Pro Ala Asn Met Phe Tyr Ile Val Ala Cys Asp
233           100          105          110
234 Asn Arg Asp Gln Arg Arg Asp Pro Pro Gln Tyr Pro Val Val Pro Val
235           115          120          125

```

RAW SEQUENCE LISTING

DATE: 12/07/2006

PATENT APPLICATION: US/10/550,632

TIME: 14:17:58

Input Set : N:\efs\12_07_06\10550632_efs\seqlist.txt

Output Set: N:\CRF4\12072006\J550632.raw

```

236 His Leu Asp Arg Ile Ile
237      130
240 <210> SEQ ID NO: 8
241 <211> LENGTH: 17
242 <212> TYPE: PRT
243 <213> ORGANISM: Homo sapiens
245 <400> SEQUENCE: 8
246 Tyr Ala Gln Thr Pro Ala Asn Met Phe Tyr Ile Val Ala Cys Asp Asn
247 1          5          10          15
248 Arg
252 <210> SEQ ID NO: 9
253 <211> LENGTH: 15
254 <212> TYPE: PRT
255 <213> ORGANISM: Homo sapiens
257 <220> FEATURE:
258 <221> NAME/KEY: PEPTIDE
259 <222> LOCATION: (1)...(15)
260 <223> OTHER INFORMATION: A Cardiovascular disorder Plasma Polypeptide 9
261      (CPP-9) peptide. SEQ ID NOs:8, 9, and 10 are the
262      amino acid sequences of tryptic peptides found by
263      MS-MS mass spectrometry in plasma samples of
W--> 264      individuals with coronary artery disease.
266 <400> SEQUENCE: 9
267 Arg Asp Pro Pro Gln Tyr Pro Val Val Pro Val His Leu Asp Arg
268 1          5          10          15
271 <210> SEQ ID NO: 10
272 <211> LENGTH: 14
273 <212> TYPE: PRT
274 <213> ORGANISM: Homo sapiens
276 <220> FEATURE:
277 <221> NAME/KEY: PEPTIDE
278 <222> LOCATION: (1)...(14)
279 <223> OTHER INFORMATION: A Cardiovascular disorder Plasma Polypeptide 9
280      (CPP-9) peptide. SEQ ID NOs:8, 9, and 10 are the
281      amino acid sequences of tryptic peptides found by
282      MS-MS mass spectrometry in plasma samples of
W--> 283      individuals with coronary artery disease.
285 <400> SEQUENCE: 10
286 Asp Pro Pro Gln Tyr Pro Val Val Pro Val His Leu Asp Arg
287 1          5          10
290 <210> SEQ ID NO: 11
291 <211> LENGTH: 151
292 <212> TYPE: PRT
293 <213> ORGANISM: Homo sapiens
295 <220> FEATURE:
296 <221> NAME/KEY: PEPTIDE
297 <222> LOCATION: (1)...(151)
298 <223> OTHER INFORMATION: A Cardiovascular disorder Plasma Polypeptide 21
299      (CPP-21) peptide. SEQ ID NO:11 describes the amino

```

VERIFICATION SUMMARY

DATE: 12/07/2006

PATENT APPLICATION: US/10/550,632

TIME: 14:17:59

Input Set : N:\efs\12_07_06\10550632_efs\seqlist.txt

Output Set: N:\CRF4\12072006\J550632.raw

L:20 M:271 C: Current Filing Date differs, Replaced Current Filing Date
L:56 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:57 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:86 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:87 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:116 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:117 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:136 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:137 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:156 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:157 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:178 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:217 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:264 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:283 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:302 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:303 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:340 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:341 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:376 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:377 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:398 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:399 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:418 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:419 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:420 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:449 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:450 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:451 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:478 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:479 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:480 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:501 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:502 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:523 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:524 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:543 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:544 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:563 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:564 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:583 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:584 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:603 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:604 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:623 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:624 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:653 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:654 M:259 W: Allowed number of lines exceeded, <223> Other Information:

VERIFICATION SUMMARY

PATENT APPLICATION: US/10/550,632

DATE: 12/07/2006

TIME: 14:17:59

Input Set : N:\efs\12_07_06\10550632_efs\seqlist.txt

Output Set: N:\CRF4\12072006\J550632.raw

L:681 M:259 W: Allowed number of lines exceeded, <223> Other Information:

L:702 M:259 W: Allowed number of lines exceeded, <223> Other Information:

L:721 M:259 W: Allowed number of lines exceeded, <223> Other Information: